Press Releases

Date   Headline
Feb 24, 2015 Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress
Feb 23, 2015 Cleveland BioLabs to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, February 24, 2015
Feb 18, 2015 Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
Feb 17, 2015 Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
Feb 11, 2015 Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Feb 10, 2015 Cleveland BioLabs Announces Annual Meeting
Feb 05, 2015 Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Feb 04, 2015 Cleveland BioLabs Announces $4.2 Million Financing
Jan 29, 2015 Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Jan 28, 2015 Cleveland BioLabs Announces Board Appointment
Jan 27, 2015 Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
Jan 12, 2015 Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
Jan 06, 2015 Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
Nov 13, 2014 Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Nov 05, 2014 Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue